← Leaderboards
Miriam S. Braunstein
Univ Of North Carolina Chapel Hill
$8,640,200
Attributed
$14,499,045
Total exposure
13
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,499,045 · 13
By mechanism
R01$11,708,003 · 5
R21$2,548,895 · 6
R03$142,144 · 1
U54$100,003 · 1
Top collaborators
- Anthony James Hickey7 shared
- Mercedes Gonzalez-Juarrero5 shared
- Bernd Meibohm5 shared
- James C Sacchettini5 shared
- Albert A Bowers2 shared
- Stephen Vernon Frye2 shared
- William Perry Janzen2 shared
- Gauri G Rao2 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Brian M Button$7,838,604
- Beverly H Koller$30,354,187
- Marcel Yotebieng$12,368,324
- Dirk P Dittmer$32,603,888
- Andrea C Weathers$224,991
Others in their field
Top investigators on “Tuberculosis”
- Judith S. Currier · University Of California Los Angeles$301,722,065
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$297,204,160
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$267,912,117
- Lawrence Corey · Fred Hutchinson Cancer Center$255,939,398
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$200,192,298
- Sharon A Nachman · Johns Hopkins University$194,852,226
Research focus
TuberculosisMycobacterium TuberculosisPharmaceutical PreparationsInfectionGenus MycobacteriumBacteriaMacrophageCell EnvelopeNovel TherapeuticsGrowthEnvironmentProtein Export PathwayAntitubercular AgentsCytoplasmProteinsVirulencePathway InteractionsFutureMycobacterialWorld HealthPathogenNovel StrategiesPlayMutant
Grant awards (39)
In vivo assessment and optimization of phage PK/PD for the treatment of pulmonary Mycobacterium abscessus infection$764,080
R01 · FY2025 · AI · contact PI
In vivo assessment and optimization of phage PK/PD for the treatment of pulmonary Mycobacterium abscessus infection$816,995
R01 · FY2024 · AI · contact PI
A novel protein export chaperone of Mycobacterium tuberculosis$508,167
R01 · FY2024 · AI · contact PI
A novel protein export chaperone of Mycobacterium tuberculosis$503,960
R01 · FY2023 · AI · contact PI
A novel protein export chaperone of Mycobacterium tuberculosis$521,036
R01 · FY2022 · AI · contact PI
Effect of Microenvironment on the Activity of Mycobacteriophages for Treating Mycobacterium abscessus$194,375
R21 · FY2022 · AI · contact PI
A novel protein export chaperone of Mycobacterium tuberculosis$573,838
R01 · FY2021 · AI · contact PI
Effect of Microenvironment on the Activity of Mycobacteriophages for Treating Mycobacterium abscessus$233,250
R21 · FY2021 · AI · contact PI
Aerosol spectinamide-1599 therapy against tuberculosis$710,674
R01 · FY2020 · AI
A novel protein export chaperone of Mycobacterium tuberculosis$598,742
R01 · FY2020 · AI · contact PI
Aerosol spectinamide-1599 therapy against tuberculosis$729,832
R01 · FY2019 · AI
Dual mechanism thiopeptide analogs for TB drug development$225,800
R21 · FY2019 · AI · contact PI
Systematic analysis of components of mycobacterial Mce transporters$192,494
R21 · FY2019 · AI · contact PI
Aerosol spectinamide-1599 therapy against tuberculosis$668,501
R01 · FY2018 · AI
Systematic analysis of components of mycobacterial Mce transporters$230,992
R21 · FY2018 · AI · contact PI
Inhaled pyrazinoic acid for tuberculosis therapy$220,013
R21 · FY2018 · AI · contact PI
Dual mechanism thiopeptide analogs for TB drug development$187,142
R21 · FY2018 · AI · contact PI
Aerosol spectinamide-1599 therapy against tuberculosis$848,545
R01 · FY2017 · AI
Inhaled pyrazinoic acid for tuberculosis therapy$281,762
R21 · FY2017 · AI · contact PI
Aerosol spectinamide-1599 therapy against tuberculosis$629,894
R01 · FY2016 · AI
Targeting SecA1 of Mycobacterium tuberculosis for Novel Drug Development$230,399
R21 · FY2015 · AI · contact PI
Developing High-Throughput Assays for M. tuberculosis Tat Pathway Inhibitors$370,000
R01 · FY2014 · AI · contact PI
Targeting SecA1 of Mycobacterium tuberculosis for Novel Drug Development$186,787
R21 · FY2014 · AI · contact PI
Developing High-Throughput Assays for M. tuberculosis Tat Pathway Inhibitors$347,800
R01 · FY2013 · AI · contact PI
Protein Secretion Pathways of Mycobacterium tuberculosis$305,031
R01 · FY2013 · AI · contact PI
Developing High-Throughput Assays for M. tuberculosis Tat Pathway Inhibitors$370,000
R01 · FY2012 · AI · contact PI
Protein Secretion Pathways of Mycobacterium tuberculosis$324,501
R01 · FY2012 · AI · contact PI
Protein Secretion Pathways of Mycobacterium tuberculosis$324,501
R01 · FY2011 · AI · contact PI
Protein Secretion Pathways of Mycobacterium tuberculosis$327,778
R01 · FY2010 · AI · contact PI
Protein Secretion Pathways of Mycobacterium tuberculosis$330,439
R01 · FY2009 · AI · contact PI
A Reporter Transposon for Studying Exported Proteins of M. tuberculosis$184,386
R21 · FY2009 · AI · contact PI
A Reporter Transposon for Studying Exported Proteins of M. tuberculosis$181,495
R21 · FY2008 · AI · contact PI
Innate Immune Responses to Pro-Apoptotic BCG$100,003
U54 · FY2008 · AI · contact PI
Protein Secretion Pathways of Mycobacterium tuberculosis$276,171
R01 · FY2007 · AI · contact PI
Identification of M. tuberculosis Protein Secreted During Growth in Macrophages$70,026
R03 · FY2007 · AI · contact PI
Protein Secretion Pathways of Mycobacterium tuberculosis$284,420
R01 · FY2006 · AI · contact PI
Identification of M. tuberculosis Protein Secreted During Growth in Macrophages$72,118
R03 · FY2006 · AI · contact PI
Protein Secretion Pathways of Mycobacterium tuberculosis$291,264
R01 · FY2005 · AI
Protein Secretion Pathways of Mycobacterium tuberculosis$281,834
R01 · FY2004 · AI